Shareholding disclosure

Jeffrey Steven Yass

Declared position

9.952%

Threshold

Crossed upwards

Timeline

Published

28.01.2025

Transaction

25.04.2024

Transfer date

29.01.2025

Voting rights breakdown

Voting rights acquired9.952%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

ZA01-000000000PNA7

Beneficial owner

Jeffrey Steven Yass

Declared address

Jeffrey Steven Yass, 19004 Bala Cynwyd PA, US

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Jeffrey Steven Yass

Newron Pharmaceuticals S.p.A.28.01.2025ZA01-000000000PNA7

Disclosure summary

Jeffrey Steven Yass disclosed a holding in Newron Pharmaceuticals S.p.A. on the acquisition side, published by SIX Exchange Regulation on 28.01.2025, at 9.952% of voting rights. Notice category: Single shareholder.

Disclosed position

9.952%

Voting rights acquired

Voting rights acquired9.952%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Jeffrey Steven Yass disclosed a holding in Newron Pharmaceuticals S.p.A., published on 28.01.2025.

Publication date28.01.2025

Transaction date25.04.2024

Transfer date29.01.2025

Issuing companyNewron Pharmaceuticals S.p.A.

Beneficial ownerJeffrey Steven Yass

Declared addressJeffrey Steven Yass, 19004 Bala Cynwyd PA, US

CategorySingle shareholder

Voting rights acquired9.952%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDZA01-000000000PNA7

Source: SIX Exchange Regulation · Publication date: 28.01.2025

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open